All News
Filter News
Found 2,543 articles
-
Moderna Announces Publication of Phase 1 Data for mRNA Vaccines Against Two Potential Pandemic Influenza Strains
5/10/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of results from two Phase 1 clinical studies showing that mRNA vaccines against H10N8 and H7N9 influenza viruses were well-tolerated and elicited robust immune responses.
-
Boston and its surrounding communities, particularly the community of Cambridge, have become the hottest biotech hotspot on the East Coast of the United States.
-
Moderna Reports First Quarter 2019 Financial Results and Provides Business Updates
5/8/2019
Rare Diseases: New development candidate announced for glycogen storage disease type 1a (GSD1a), a rare metabolic disorder; Company now has five rare disease programs in its pipeline
-
Moderna to Present at Bank of America Merrill Lynch 2019 Health Care Conference
5/6/2019
Moderna, Inc. announced that Tal Zaks, M.D., Ph.D., Chief Medical Officer, and Lorence Kim, M.D., Chief Financial Officer, will present at the Bank of America Merrill Lynch 2019 Health Care Conference on Tuesday, May 14, 2019 at 9:20 a.m. PT.
-
The annual meeting of the American Society of Gene & Cell Therapy (ASGCT) was held in Washington, DC this week, with literally hundreds of abstracts and presentations. Here’s a look at some of the highlights.
-
Moderna to Present Preclinical Data at 2019 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
4/29/2019
The Company and academic collaborators to share data from seven preclinical studies demonstrating the potential of mRNA-based therapies to treat rare metabolic and genetic disorders
-
Flagship Pioneering Unveils Kintai Therapeutics and Appoints Pharmaceutical Drug Developer Paul-Peter Tak, M.D., Ph.D., as Chief Executive Officer
4/16/2019
Just two years since its founding by Flagship Labs, the company has elucidated a new understanding of the multimodal enteric system, translating this insight into 10+ therapeutic programs
-
Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019
4/16/2019
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day for analysts and investors on Tuesday, May 7, 2019 at 8:00 a.m. ET in Cambridge, MA.
-
Life science incubators and accelerators play a highly significant role in the industry and may be the key for regional growth, a new report shows.
-
Moderna to Present at 18th Annual Needham Healthcare Conference
4/3/2019
Moderna, Inc. announced that Tal Zaks, M.D., Ph.D., Moderna’s Chief Medical Officer, will participate in a fireside chat at the 18th Annual Needham Healthcare Conference on Wednesday, April 10, 2019 at 11:20 a.m. ET.
-
DPS Group and TRIA Congratulate Moderna on ISPE 2019 Facility of the Future Category Award
4/2/2019
Moderna's cGMP clinical development manufacturing facility takes category win in the 2019 ISPE Facility of the Year Award Program
-
DPS Group Promotes Jim Grunwald to Senior Vice President, U.S. Business Development
4/1/2019
DPS Group, a privately-owned, global engineering, procurement, construction management and validation (EPCMV) firm serving high-tech process industries, is pleased to announce that Jim Grunwald has been promoted to senior vice president for U.S. business development
-
Flagship Pioneering closed out a monster pool of funds to support a number of pioneering life science companies. Cambridge, Mass.-based Flagship secured $824 million in a new capital pool to boost companies that launch from its Flagship Labs incubator unit.
-
Flagship Pioneering Expands Growth Capabilities, Announces Capital Raise of $824MM
3/20/2019
Flagship Pioneering, a unique life sciences innovation enterprise, announced it has secured $824 million in a new capital pool to support the growth of human health and sustainability companies originated by its Flagship Labs unit.
-
From New Treatments To Changing Policies, Industry Leaders Discuss Changing Healthcare Landscape At Oppenheimer & Co. Inc's Annual Conference
3/19/2019
The Marwood Group will present the keynote lunch address on Tuesday, while Wednesday's keynote lunch speaker will be Dr. Jason Luke from the University of Chicago, who will address how to spot red flags in early clinical trials.
-
Coming off its record-breaking initial public offering (IPO) in December, where it raised $604.3 million, Moderna released its fourth-quarter financials, outlining an ambitious company buzzing with activity.
-
Moderna to Present at Upcoming Investor Conferences in March
3/4/2019
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced its participation in the following upcoming investor conferences:
-
Evaluate recently published the Vantage Pharma, Biotech and Medtech 2018 in review report. The annual report offers insights into the previous year’s activities in biopharma and the medical device industry.
-
Biopharma in 2018: Vantage Releases Annual Analysis of Pharma, Biotech and Medtech Performance
2/26/2019
A year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong
-
Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019
2/21/2019
Moderna, Inc. announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, March 6, 2019 to report its fourth quarter and full year 2018 financial results and provide a corporate update.